27 completed, 3 active not recruiting, 2 enrolling by invitation, 1 recruiting. 35 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 35 | Completed 27, Active not recruiting 3, Enrolling by invitation 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 4, Enrolling by invitation 1, Withdrawn 1 |
Follow Hereditary Angioedema: new trials by email Literature Review of Hereditary Angioedema trials Research Report on Hereditary Angioedema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STOP-HAE: A Phase 3 Study of ADX-324 in HAE ADX-324, Placebo - Hereditary Angioedema, HAE | Phase 3 | Recruiting | ADARx Pharmaceuticals, Inc. | 90 | 2025-08-28 | 2026-09-10 |
| HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) NTLA-2002, Normal Saline IV Administration - Hereditary Angioedema | Phase 3 | Active not recruiting | Intellia Therapeutics | 80 | 2025-01-15 | 2026-10-08 |
| Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II KVD900 150 mg, KVD900 300 mg, KVD900 600 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 36 | 2024-08-01 | 2026-08-05 |
| Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 3 | Completed | Pharvaris Netherlands B.V. | 134 | 2024-02-26 | 2025-11-21 |
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
| Berotralstat Treatment in Children With Hereditary Angioedema Berotralstat - Hereditary Angioedema, Pediatric | Phase 3 | Active not recruiting | BioCryst Pharmaceuticals | 29 | 2022-10-25 | 2026-02-25 |
| An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) KVD900 600 mg, KVD900 300 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 145 | 2022-10-24 | 2026-06-05 |
| PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial KVD900 600 mg, Drug: KVD900 300 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 11 | 2022-10-24 | 2026-06-08 |
| A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) Donidalorsen - Hereditary Angioedema | Phase 3 | Active not recruiting | Ionis Pharmaceuticals, Inc. | 154 | 2022-07-13 | 2025-12-12 |
| A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) Placebo, KVD900 600 mg, KVD900 300 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 136 | 2022-02-22 | 2025-05-02 |
| OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE) Donidalorsen, Placebo - Hereditary Angioedema | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 91 | 2021-12-03 | 2025-03-06 |
| Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema GNR-038, 50 МЕ/ kg, GNR-038, 100 МЕ/ kg, Berinert®, 20 МЕ/ kg - Hereditary Angioedema | Phase 2 / Phase 3 | Withdrawn | AO GENERIUM | 2021-12-01 | 2022-02-04 | |
| Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies berotralstat - Hereditary Angioedema, HAE | Phase 3 | Enrolling by invitation | BioCryst Pharmaceuticals | 139 | 2021-07-23 | 2025-12-23 |
| Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks CSL312 - Hereditary Angioedema | Phase 3 | Completed | CSL Behring | 171 | 2021-03-29 | 2026-06-02 |
| Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema TAK-743 300 mg - Hereditary Angioedema | Phase 3 | Completed | Takeda | 12 | 2021-02-10 | 2023-06-26 |
| CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks CSL312, Placebo - Hereditary Angioedema | Phase 3 | Completed | CSL Behring | 64 | 2021-01-27 | 2023-06-29 |
| A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema TAK-667 - Hereditary Angioedema | Phase 3 | Completed | Takeda | 2 | 2021-01-15 | 2022-03-29 |
| A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children Lanadelumab - Hereditary Angioedema | Phase 3 | Completed | Shire | 21 | 2019-08-19 | 2022-05-26 |
| A Long Term Safety Study of BCX7353 in Hereditary Angioedema BCX7353 - Hereditary Angioedema, HAE | Phase 2 / Phase 3 | Completed | BioCryst Pharmaceuticals | 387 | 2018-02-16 | 2023-06-18 |
| Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE BCX7353 capsules, Placebo oral capsule - Hereditary Angioedema, HAE | Phase 3 | Completed | BioCryst Pharmaceuticals | 121 | 2018-02-06 | 2023-06-26 |
Showing 20 of 35. Sign in to see all of them.
Angioedemas, Hereditary (35) · Angioedema (4) · Genetic Diseases, Inborn (2) · Hereditary Angioedema Type III (2) · Hereditary Angioedema Types I and II (2) · Hypersensitivity (1) · Immune System Diseases (1)
Cardiovascular Diseases (35) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (35) · Hereditary Complement Deficiency Diseases (35) · Hypersensitivity, Immediate (35) · Immunologic Deficiency Syndromes (35) · Primary Immunodeficiency Diseases (35) · Skin Diseases (35) · Skin Diseases, Vascular (35) · Skin and Connective Tissue Diseases (35) · Urticaria (35) · Vascular Diseases (35) · Hypersensitivity (34) · Immune System Diseases (34) · Genetic Diseases, Inborn (33) · Angioedema (31)
Complement C1 Inhibitor Protein (10) · Sodium Chloride (6) · berotralstat (4) · icatibant (4) · sebetralstat (4) · avoralstat (2) · conestat alfa (2) · donidalorsen (2) · lanadelumab (2) · IONIS-PKK-LRx (1) · RNA, Small Interfering (1) · Tranexamic Acid (1)
Shire (8) · BioCryst Pharmaceuticals (6) · CSL Behring (4) · KalVista Pharmaceuticals, Ltd. (4) · Pharming Technologies B.V. (3) · Ionis Pharmaceuticals, Inc. (2) · Pharvaris Netherlands B.V. (2) · Takeda (2) · ADARx Pharmaceuticals, Inc. (1) · AO GENERIUM (1) · Intellia Therapeutics (1) · Johann Wolfgang Goethe University Hospital (1)
United States (24) · Canada (21) · Germany (20) · France (17) · Israel (16) · Spain (16) · United Kingdom (16) · Hungary (14) · Italy (14) · Netherlands (12) · Poland (12) · Australia (11) · Bulgaria (10) · Japan (10) · Romania (10)
Anurag Relan, MD (1) · Bruce Zuraw, MD (1) · Henriette Farkas, MD (1) · Henriette Farkas, MD, PhD, DSc (1) · Jan Nuijens, MD, PhD (1) · Jolanta Bernatoniene, MD (1) · Lauge Farnaes, MD (1) · Marc Riedl, MD MS (1) · Oksana A. Markova, MD (1) · Vesna Grivcheva-Panoska, MD, PhD (1) · Wolfhart Kreuz, PD Phd (1)
PMID 36326435, PMID 20818886, PMID 23312695, PMID 42159953, PMID 20920772, PMID 22856635, PMID 23484892, PMID 23987198, PMID 28284978, PMID 36408587, PMID 40380356, PMID 40886933, PMID 42268494, PMID 17073887, PMID 19767078, PMID 20674826, PMID 20818888, PMID 21195947, PMID 21884533, PMID 22123383, PMID 22192966, PMID 22856636, PMID 22909164, PMID 23167682, PMID 23535096, PMID 24111645, PMID 24266596, PMID 24438203, PMID 25198193, PMID 25295804, PMID 26556097, PMID 33098856, PMID 33866032, PMID 34161665, PMID 35820771, PMID 36774155, PMID 36868261, PMID 37730089, PMID 38006972, PMID 38020288, PMID 38819395, PMID 40380363, PMID 40490218, PMID 40673861, PMID 40716738, PMID 41208217, PMID 41252457, PMID 41767175, PMID 42294842, PMID 42318595
2004 (2), 2008 (1), 2009 (1), 2018 (1), 2023 (1)